Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bushen Tiaoyuan Tongluo Formula is a Traditional Chinese Medicine (TCM) herbal composition developed by researchers at Shanghai Pulmonary Hospital. It is designed as an adjuvant therapy to be used in combination with standard-of-care treatments, such as PD-1 inhibitors and chemotherapy, for patients with advanced non-small cell lung cancer (NSCLC). Based on TCM principles, the formula aims to tonify the kidney, regulate primordial Qi, and unblock collaterals, which is hypothesized to enhance the body's immune response and improve the tumor microenvironment. Clinical evaluation focuses on its ability to improve progression-free survival (PFS) and quality of life in lung cancer patients receiving systemic immunotherapy and chemotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bushen tiaoyuan tongluo formula.